Neutrophils in Sepsis: Role of CIRP
脓毒症中的中性粒细胞:CIRP 的作用
基本信息
- 批准号:9580383
- 负责人:
- 金额:$ 33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Lung InjuryAdoptive TransferAntibodiesAttenuatedBindingBloodBlood CirculationBone MarrowCellsChromatinDevelopmentDiseaseDoseEndothelial CellsEnvironmentFDA approvedGoalsHistologyHumanImmune responseIn Situ Nick-End LabelingIn VitroInfectionInflammationInflammation MediatorsInjectionsInjuryIntercellular adhesion molecule 1Interleukin-1 betaInterleukin-6InternetKidneyKnock-outKnockout MiceLeukocytesLifeLigandsLiverLungMacrophage-1 AntigenMeasuresMolecularMorbidity - disease rateMouse ProteinMusNeutrophil ActivationNuclearNuclear ProteinPECAM1 genePathway interactionsPatientsPatternPeptidesPeroxidasesPharmaceutical PreparationsProtein-arginine deiminaseProteinsRNA-Binding ProteinsReactive Oxygen SpeciesRecombinantsRoleSepsisSerumSeveritiesSignal PathwaySurfaceSyndromeTLR4 geneTNF geneTherapeutic EffectTimeTissuesVascular Cell Adhesion Molecule-1Wild Type Mousebasececal ligation puncturechemokineclinical developmentcytokineeffective therapyextracellularimprovedin vivoinhibitor/antagonistlung injurymacrophagemortalityneutralizing antibodyneutrophilnovelnovel therapeutic interventionpreclinical developmentpublic health relevancereceptorseptic
项目摘要
PROJECT DESCRIPTION: This R01 project's goal is to investigate the mechanism by which cold-inducible
RNA-binding protein (CIRP) increases sepsis severity and causes acute lung injury (ALI). Sepsis and ALI are
deadly and have no FDA-approved treatment. CIRP is a nuclear protein that can be released into the
circulation during sepsis, increasing sepsis severity and causing ALI. We have discovered that CIRP
increases a novel subset of neutrophils characterized by surface expression of intercellular adhesion molecule-
1 (ICAM-1). We found that ICAM-1+ neutrophils were expanded in the blood and lungs of septic mice, but not
in CIRP knockout mice. We further showed that stimulation with CIRP was sufficient to induce ICAM-1+
neutrophils. For the first time, we discovered that CIRP-induced ICAM-1+ neutrophils produced much higher
levels of neutrophil extracellular traps (NETs). Based on these novel findings, we hypothesize that CIRP
induces NET-forming ICAM-1+ neutrophils to cause ALI in sepsis. We also showed that C23, a peptide derived
from human CIRP, dose-dependently inhibits CIRP-induced release of TNF-α and inhibits CIRP induction of
ICAM-1+ neutrophils. Thus, we further hypothesize that C23 attenuates sepsis-induced ALI by reducing CIRP-
induced NET-forming neutrophils. We will first demonstrate CIRP's induction of NET-forming ICAM-1+
neutrophils and their deleterious effects, both in vitro and in vivo. Next, we will identify key signaling pathways
through which CIRP induces NET-forming ICAM-1+ neutrophils. Finally, we will examine C23's ability to
suppress NET-forming ICAM-1+ neutrophils, decrease sepsis and ALI severity, and increase sepsis survival.
These studies will improve our understanding of how CIRP induces NET-forming neutrophils to cause
inflammation and tissue injury and support the development of C23 as a new and effective treatment for
patients with sepsis and ALI.
项目描述:这个R 01项目的目标是研究冷诱导的
RNA结合蛋白(CIRP)增加脓毒症的严重程度,并导致急性肺损伤(ALI)。脓毒症和急性肺损伤
没有FDA批准的治疗方法CIRP是一种核蛋白,可以被释放到细胞中。
脓毒症期间的血液循环,增加脓毒症的严重程度并引起ALI。我们发现CIRP
增加了一个新的中性粒细胞亚群,其特征是细胞间粘附分子的表面表达,
1(ICAM-1)。我们发现,ICAM-1+中性粒细胞在脓毒症小鼠的血液和肺中扩增,但在脓毒症小鼠的血液和肺中没有扩增。
在CIRP敲除小鼠中。我们进一步表明,用CIRP刺激足以诱导ICAM-1+表达。
中性粒细胞我们第一次发现CIRP诱导的ICAM-1+中性粒细胞产生了更高的ICAM-1,
中性粒细胞胞外陷阱(NETs)。基于这些新的发现,我们假设CIRP
诱导NET形成ICAM-1+中性粒细胞引起脓毒症中的ALI。我们还表明,C23,一种肽衍生物,
从人CIRP中,剂量依赖性地抑制CIRP诱导的TNF-α释放,
ICAM-1+中性粒细胞。因此,我们进一步假设C23通过降低CIRP-1来减弱脓毒症诱导的ALI。
诱导NET形成中性粒细胞。我们将首先证明CIRP诱导NET形成ICAM-1+
中性粒细胞及其有害作用,在体外和体内。接下来,我们将确定关键的信号通路
CIRP通过其诱导NET形成ICAM-1+中性粒细胞。最后,我们将研究C23的能力,
抑制NET形成ICAM-1+中性粒细胞,降低脓毒症和ALI严重程度,并增加脓毒症存活率。
这些研究将提高我们对CIRP如何诱导NET形成中性粒细胞引起
炎症和组织损伤,并支持C23作为一种新的有效治疗方法的发展,
脓毒症和ALI患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Monowar Aziz其他文献
Monowar Aziz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Monowar Aziz', 18)}}的其他基金
Mechanisms of Radiation-Induced Innate Immune Dysfunction and Its Countermeasures
辐射引起的先天性免疫功能障碍的机制及对策
- 批准号:
10474023 - 财政年份:2022
- 资助金额:
$ 33万 - 项目类别:
Mechanisms of Radiation-Induced Innate Immune Dysfunction and Its Countermeasures
辐射引起的先天性免疫功能障碍的机制及对策
- 批准号:
10669714 - 财政年份:2022
- 资助金额:
$ 33万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 33万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 33万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 33万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 33万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 33万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 33万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 33万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 33万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 33万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 33万 - 项目类别: